<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="45187">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01860326</url>
  </required_header>
  <id_info>
    <org_study_id>CDEB025A2114</org_study_id>
    <nct_id>NCT01860326</nct_id>
  </id_info>
  <brief_title>Evaluate the Pharmacokinetics, Safety, and Tolerability of DEB025 in Subjects With Hepatic Impairment Compared to Healthy Subjects</brief_title>
  <official_title>An Open-label Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Single Oral Doses of DEB025 in Subjects With Mild and Moderate Hepatic Impairment Compared to Matched Healthy Subjects With Normal Liver Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label study to evaluate the pharmacokinetics, safety and tolerability of
      single oral doses of DEB025 in subjects with mild and moderate hepatic impairment compared
      to matched healthy subjects with normal liver function.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Pharmacokinetic assessment of DEB025</measure>
    <time_frame>0-168 hrs after treatment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of DEB025</measure>
    <time_frame>8 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Vital signs, electrocardiograms, labs, and adverse events.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Mild and Moderate Hepatic Impairment</condition>
  <arm_group>
    <arm_group_label>DEB025</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DRUG</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DEB025</intervention_name>
    <description>DEB025 single oral dose</description>
    <arm_group_label>DEB025</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Male or female, 18 to 70 years of age, in good health

          -  Stable Child-Turcotte-Pugh score of at least 5

          -  Body weight of at least 50 kg and a BMI of 18.0 to 36.0 kg/m2

        Exclusion criteria:

          -  Use of other investigational drugs

          -  Women of child-bearing potential

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 19, 2013</lastchanged_date>
  <firstreceived_date>February 21, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hepatic impairment</keyword>
  <keyword>DEB025A</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
